IL151551A0 - Crystalline pharmaceutical - Google Patents

Crystalline pharmaceutical

Info

Publication number
IL151551A0
IL151551A0 IL15155101A IL15155101A IL151551A0 IL 151551 A0 IL151551 A0 IL 151551A0 IL 15155101 A IL15155101 A IL 15155101A IL 15155101 A IL15155101 A IL 15155101A IL 151551 A0 IL151551 A0 IL 151551A0
Authority
IL
Israel
Prior art keywords
crystalline pharmaceutical
crystalline
pharmaceutical
Prior art date
Application number
IL15155101A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL151551(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL151551A0 publication Critical patent/IL151551A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15155101A 2000-03-30 2001-03-21 Crystalline pharmaceutical IL151551A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical
PCT/US2001/009112 WO2001074787A2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
IL151551A0 true IL151551A0 (en) 2003-04-10

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15155101A IL151551A0 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical

Country Status (22)

Country Link
EP (1) EP1268442A2 (xx)
JP (1) JP2003529592A (xx)
KR (1) KR100773258B1 (xx)
CN (2) CN1330639C (xx)
AR (2) AR033360A1 (xx)
AU (3) AU5092001A (xx)
BG (1) BG107165A (xx)
BR (1) BR0109433A (xx)
CA (1) CA2403635A1 (xx)
CZ (1) CZ20023529A3 (xx)
HU (1) HUP0302675A3 (xx)
IL (1) IL151551A0 (xx)
MX (1) MXPA02009559A (xx)
MY (1) MY128296A (xx)
NO (1) NO325005B1 (xx)
NZ (1) NZ521183A (xx)
PE (1) PE20011232A1 (xx)
PL (1) PL359727A1 (xx)
SA (2) SA06270303B1 (xx)
SK (1) SK14832002A3 (xx)
TW (1) TWI284640B (xx)
WO (1) WO2001074787A2 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
ES2459301T3 (es) * 2009-02-06 2014-05-08 Hetero Research Foundation Nuevos polimorfos de lopinavir
US8637449B2 (en) * 2009-08-27 2014-01-28 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
AR049560A2 (es) 2006-08-16
CN101066952A (zh) 2007-11-07
CZ20023529A3 (cs) 2003-02-12
BR0109433A (pt) 2004-08-10
NO20024679L (no) 2002-09-30
SA01220270B1 (ar) 2006-11-14
HUP0302675A3 (en) 2004-03-29
TWI284640B (en) 2007-08-01
NZ521183A (en) 2004-03-26
WO2001074787A2 (en) 2001-10-11
CA2403635A1 (en) 2001-10-11
PE20011232A1 (es) 2001-12-08
MY128296A (en) 2007-01-31
AU2006222711A1 (en) 2006-10-19
NO325005B1 (no) 2008-01-14
WO2001074787A3 (en) 2002-02-07
SA06270303B1 (ar) 2009-08-02
JP2003529592A (ja) 2003-10-07
MXPA02009559A (es) 2003-05-21
CN1422259A (zh) 2003-06-04
CN1330639C (zh) 2007-08-08
AU2001250920B2 (en) 2006-06-29
KR20030011807A (ko) 2003-02-11
EP1268442A2 (en) 2003-01-02
NO20024679D0 (no) 2002-09-30
PL359727A1 (en) 2004-09-06
KR100773258B1 (ko) 2007-11-05
BG107165A (bg) 2003-07-31
AU5092001A (en) 2001-10-15
SK14832002A3 (sk) 2003-02-04
AR033360A1 (es) 2003-12-17
HUP0302675A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
GB0006133D0 (en) Novel pharmaceutical
GB0020691D0 (en) Pharmaceutical combination
GB0025473D0 (en) Pharmaceutical combinations
GB0031084D0 (en) Pharmaceutical compounds
GB0012291D0 (en) Pharmaceutical combination
GB0019272D0 (en) Pharmaceutical compounds
GB0019228D0 (en) Novel pharmaceutical
GB0021865D0 (en) Novel pharmaceutical
AU5092001A (en) Crystalline pharmaceutical
GB0129273D0 (en) Crystalline drug form
GB0024318D0 (en) Pharmaceutical compounds
GB0014006D0 (en) Novel pharmaceutical
GB0019226D0 (en) Novel pharmaceutical
GB0019224D0 (en) Novel pharmaceutical
GB0005366D0 (en) Pharmaceutical compounds
GB0021487D0 (en) Pharmaceutical
GB0014005D0 (en) Novel pharmaceutical
GB0023971D0 (en) Novel pharmaceutical
GB0021785D0 (en) Novel Pharmaceutical
GB0023970D0 (en) Novel pharmaceutical
HRP20030067A2 (en) Novel pharmaceutical
GB0012293D0 (en) Pharmaceutical combination
GB0006601D0 (en) Crystalline alkycycline derivative
EG24200A (en) Novel pharmaceutical
GB0022520D0 (en) Pharmaceutical compounds